Sonoma Pharmaceuticals (SNOA) Change in Account Payables (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Change in Account Payables of $282000.0 for Q1 2026, up 162.95% year-over-year from $107246.2 in Q1 2025, and up 23.14% quarter-over-quarter from $229000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Change in Account Payables (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at $282000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 162.95% year-over-year to $282000.0; the TTM figure through Mar 2026 stood at $871000.0 (up 109.38% YoY), while the FY2026 annual figure was $871000.0, up 109.38% from the prior year.
- Change in Account Payables for Q1 2026 stood at $282000.0, up from $229000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.0 million in Q2 2025, with the low at -$981000.0 in Q3 2022.
- The 5-year median for Change in Account Payables is $37000.0 (2024), against an average of $10411.8.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables soared 1410.71% in 2022, then plunged 1900.0% in 2025.
- Sonoma Pharmaceuticals' Change in Account Payables stood at $205000.0 in 2022, then tumbled by 170.24% to -$144000.0 in 2023, then jumped by 547.92% to $645000.0 in 2024, then plunged by 64.5% to $229000.0 in 2025, then climbed by 23.14% to $282000.0 in 2026.
- Business Quant data shows SNOA's Change in Account Payables at $282000.0 in Q1 2026, $229000.0 in Q4 2025, and -$666000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 216,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 216,000.00 |
| Jun 30, 2026 | 216,000.00 |
| Mar 31, 2026 | 282,000.00 |
| Mar 31, 2026 | 282,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Sep 30, 2025 | -666,000.00 |
| Sep 30, 2025 | -666,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | -448,000.00 |
| Mar 31, 2025 | -448,000.00 |
| Dec 31, 2024 | 645,000.00 |
| Dec 31, 2024 | 645,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | -266,000.00 |
| Mar 31, 2024 | -266,000.00 |